Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 18/20 | 0.60 |
| ▸ | LATS2 | Q9NRM7 | 13/20 | 0.60 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | PRKCH | P24723 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650563 | 1.00 | LATS1 (0.60) | LATS1LATS2PRKCBPRKCHPRKCE | |
| SCHEMBL31375158 | 0.82 | LATS1 (0.60) | LATS1LATS2PRKCBPRKCHPRKCE | |
| SCHEMBL786755 | 0.80 | LATS1 (0.51) | LATS1LATS2 | |
| SCHEMBL20574275 | 0.78 | LATS1 (0.56) | LATS1LATS2 | |
| SCHEMBL23301086 | 0.75 | F7 (0.45) | LATS1LATS2 | |
| SCHEMBL20548299 | 0.75 | LATS1 (1.00) | LATS1LATS2PRKCBPRKCHPRKCE | |
| SCHEMBL20573806 | 0.75 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL31375902 | 0.75 | LATS1 (1.00) | LATS1LATS2 | |
| SCHEMBL29897374 | 0.75 | F7 (0.45) | LATS1LATS2 | |
| SCHEMBL246231 | 0.75 | LATS1 (0.43) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615537-B1 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| CN-110573511-B | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | NOVARTIS AG (CH) | 2022-10-04 | — | — | US | disclosed |
| CN-114703144-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114621222-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3615537-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | Novartis AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| CN-110573511-A | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS AG (CH) | 2018-12-06 | — | — | US | disclosed |
| WO-2018198077-A2 | 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS | NOVARTIS AG (CH) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458138-B2 | 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCB 1648/4885 |
| US-20180344738-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCB 1648/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | LATS1 1/4885LATS2 2/4885PRKCB 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.